{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Anti-viral",
      "Clinical guidelines",
      "In vitro",
      "Pharmacokinetic",
      "Viral clearance"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33130203",
  "DateCompleted": {
    "Year": "2021",
    "Month": "01",
    "Day": "18"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2020",
        "Month": "10",
        "Day": "30"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.ijid.2020.10.069",
      "S1201-9712(20)32273-6"
    ],
    "Journal": {
      "ISSN": "1878-3511",
      "JournalIssue": {
        "Volume": "102",
        "PubDate": {
          "Year": "2021",
          "Month": "Jan"
        }
      },
      "Title": "International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases",
      "ISOAbbreviation": "Int J Infect Dis"
    },
    "ArticleTitle": "Role of favipiravir in the treatment of COVID-19.",
    "Pagination": {
      "StartPage": "501",
      "EndPage": "508",
      "MedlinePgn": "501-508"
    },
    "Abstract": {
      "AbstractText": [
        "The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the researchers to strive to develop drugs or vaccines to prevent or halt the progression of this ailment. To hasten the treatment process, repurposed drugs are being evaluated. Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro activity against severe acute respiratory syndrome coronavirus-2. It has a wide therapeutic safety margin indicated by a wide CC50/EC50 ratio for a high dose. From the clinical studies in COVID-19, it has shown rapid viral clearance as compared to lopinavir/ritonavir (LPV/RTV) and superior recovery rate than umifenovir. Overall, favipiravir has shown promising results in clinical studies in China, Russia, and Japan, and more trials are underway in multiple countries, including USA, UK, and India. Recently, treatment guidelines from many countries and some states from India have included favipiravir in the treatment protocol. This review provides insights into the evidence-based evolving role of favipiravir in the management of COVID-19 infection with emphasis on benefits of initiating an early antiviral therapy with special focus on favipiravir, its pharmacodynamic, pharmacokinetic, in vitro, clinical data, and inclusion in the treatment protocols of COVID-19."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020 The Authors. Published by Elsevier Ltd.. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Joshi Clinic and Lilavati Hospital and Research Center, Mumbai, India."
          }
        ],
        "LastName": "Joshi",
        "ForeName": "Shashank",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lilavati Hospital and Research Center, Mumbai, India."
          }
        ],
        "LastName": "Parkar",
        "ForeName": "Jalil",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Critical Care Services, Nanavati Super Specialty Hospital, Mumbai, India."
          }
        ],
        "LastName": "Ansari",
        "ForeName": "Abdul",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Vora Clinic, Mumbai, India."
          }
        ],
        "LastName": "Vora",
        "ForeName": "Agam",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Metro Respiratory Centre, Noida, India."
          }
        ],
        "LastName": "Talwar",
        "ForeName": "Deepak",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Shilpa Medical Research Centre, Mumbai, India."
          }
        ],
        "LastName": "Tiwaskar",
        "ForeName": "Mangesh",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Global Medical Affairs, India Formulations, Glenmark Pharmaceuticals Ltd., Mumbai, India. Electronic address: saiprasad.patil@glenmarkpharma.com."
          }
        ],
        "LastName": "Patil",
        "ForeName": "Saiprasad",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Global Medical Affairs, India Formulations and Middle East Africa, Glenmark Pharmaceuticals Ltd., Mumbai, India."
          }
        ],
        "LastName": "Barkate",
        "ForeName": "Hanmant",
        "Initials": "H"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Canada",
    "MedlineTA": "Int J Infect Dis",
    "NlmUniqueID": "9610933",
    "ISSNLinking": "1201-9712"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Amides"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrazines"
    },
    {
      "RegistryNumber": "EW5GL2X7E0",
      "NameOfSubstance": "favipiravir"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Amides"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "epidemiology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Pyrazines"
    },
    {
      "QualifierName": [
        "drug effects",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}